Featured Research

from universities, journals, and other organizations

New markers could improve treatment and survival in acute lymphoblastic leukemia

Date:
December 21, 2012
Source:
Basque Research
Summary:
Acute lymphoblastic leukemia, the most common pediatric cancer, has been the subject of a new study. Newly identified genetic markers could improve the classification of risk groups and predict treatment toxicity in the patient.

Acute lymphoblastic leukemia, the most common pediatric cancer, has been the subject of study in the PhD thesis of Elixabet López. In the work entitled "New genetic markers for treatment personalization in paediatric Acute Lymphoblastic leukemia," the UPV/EHU biologist has presented new genetic markers that could improve the classification of risk groups and predict treatment toxicity in the patient. That way it would be possible to achieve better personalisation of the treatment.

Related Articles


Over the last few decades survival has increased from 10% to 80%. This improvement has been achieved by using combined therapies and separating the patients into risk groups. For example, stronger treatment is used in the groups in which a worse response is expected. That way the survival probability in the groups with a poor prognosis is increased, while chemotherapy toxicity in patients with a better prognosis is reduced.

However, the classification of the risk groups, which today is carried out by means of clinical markers, like the number of lymphocytes or age of the patient, and some genetic markers, is not totally exact. For example, some of the patients initially considered as lower risk do not respond well to the treatment and in the middle of their treatment their therapy is changed to that of greater risk. In these cases, "survival could be improved as the condition would be treated more intensively right from the start," points out López.

On the other hand, children with acute lymphoblastic leukemia receive very strong doses of chemotherapy, and toxicity problems, which can be very serious, often occur. What is more, "as they are children and the toxicity can leave them with sequelae for the rest of their lives, it is quite important to try and prevent it," says López. Currently, there is no toxicity marker that is used in a standard way.

Quest for new markers

To find new risk markers, the whole genome of tumour cells was combed in the search for deletions and duplications. And the ones that were recurrent and which were exclusive to a risk group were selected, and so were the ones that were found in the patients who were moved from one group to another. "We have found a low risk marker which only appears in low risk patients and another that only appears in high risk ones, which could complement the ones that are already being used. And another 5 markers that appear in patients that were changed from low risk to high risk, and in those of high risk. This means that those patients were in fact high risk ones and that they should have been included in that group," explains the author.

On the other hand, the toxicity markers were sought in normal cells to detect variations that are of the individual and not of the tumour. This study has focussed on methotrexate, one of the most important drugs that can cause toxicity. And several possible markers have been found, like some variants of the methotrexate transporter gene and other variants related to microRNAs (short ribonucleic acid molecules which do not give rise to proteins but which carry out a significant regulatory function) that regulate the genes.

López's next aim is to study how the genetic variations found affect gene expression and see exactly why these variations are regulating toxicity or response to treatment. Furthermore, to validate the markers, they are endeavouring to set up some clinical trials. "We have found these associations in our population, but a clinical trial would be needed to see whether they really are good markers and whether, in actual fact, survival and toxicity are improved when these markers are used," says López.


Story Source:

The above story is based on materials provided by Basque Research. Note: Materials may be edited for content and length.


Cite This Page:

Basque Research. "New markers could improve treatment and survival in acute lymphoblastic leukemia." ScienceDaily. ScienceDaily, 21 December 2012. <www.sciencedaily.com/releases/2012/12/121221081617.htm>.
Basque Research. (2012, December 21). New markers could improve treatment and survival in acute lymphoblastic leukemia. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2012/12/121221081617.htm
Basque Research. "New markers could improve treatment and survival in acute lymphoblastic leukemia." ScienceDaily. www.sciencedaily.com/releases/2012/12/121221081617.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Diné Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins